Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib

Criteria

Inclusion Criteria:

• RCC with metastases and nephrectomy

• failure of prior sorafenib-based therapy

• at least 1 target lesion that has not been irradiated

• adequate bone marrow, hepatic and renal function, > or equal to 18 years of age.

Exclusion Criteria:

• Gastrointestinal abnormalities

• current use or inability to avoid chronic antacid therapy

• current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2 inducers

• active seizure disorder or evidence of brain metastases.